Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.

To evaluate the prognostic significance of circulating tumour cell (CTC) number determined on the Epic Sciences platform in men with metastatic castration-resistant prostate cancer (mCRPC) treated with an androgen receptor signalling inhibitor (ARSI). A pre-treatment blood sample was collected from men with progressing mCRPC starting either abiraterone or enzalutamide as a first-, second- or third-line systemic therapy at Memorial Sloan Kettering Cancer Center (Discovery cohort, N = 171) or as a first- or second-line therapy as part of the multicenter PROPHECY trial (NCT02269982) (Validation cohort, N = 107). The measured CTC number was then associated with overall survival (OS) in the Discovery cohort, and progression-free survival (PFS) and OS in the Validation cohort. CTC enumeration was also performed on a concurrently obtained blood sample using the CellSearch® Circulating Tumor Cell Kit. In the MSKCC Discovery cohort, CTC count was a statistically significant prognostic factor of OS as a dichotomous (<3 CTCs/mL versus ≥ 3 CTCs/mL; hazard ratio [HR] = 1.8 [95% confidence interval {CI} 1.3-3.0]) and a continuous variable when adjusting for line of therapy, presence of visceral metastases, prostate-specific antigen, lactate dehydrogenase and alkaline phosphatase. The findings were validated in an independent datas et from PROPHECY (HR [95% CI] = 1.8 [1.1-3.0] for OS and 1.7 [1.1-2.9] for PFS). A strong correlation was also observed between CTC counts determined in matched samples on the CellSearch® and Epic platforms (r = 0.84). The findings validate the prognostic significance of pretreatment CTC number determined on the Epic Sciences platform for predicting OS in men with progressing mCRPC starting an ARSI.

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Conflict of interest statement Howard I. Scher, leadership: Asterias Biotherapeutics; stock options and other ownership interests: Asterias Biotherapeutics; honoraria: Research to Practice, consulting or advisory role: Ambry Genetics/Konica Minolta; Amgen; Bayer; ESSA; Janssen; Janssen Research & Development; Menarini Silicon Biosystems; Pfizer; WIRB-Copernicus Group, research Funding: Epic Sciences (Inst); Illumina (Inst); Janssen (Inst); Menarini Silicon Biosystems (Inst); Thermo Fisher Scientific Biomarkers (Inst); Patents, Royalties, Other Intellectual Property - BioNTech -Intellectual Property Rights; Elucida Oncology: Intellectual Property Rights; MabVAX - Intellectual Property Rights; Y-mAbs Therapeutics, Inc - Intellectual Property Rights; travel, accommodations, expenses: Amgen; Asterias Biotherapeutics; Bayer; ESSA; Konica Minolta; Menarini Silicon Biosystems; Phosplatin Therapeutics; Prostate Cancer Foundation; Sanofi; WIRB-Copernicus Group. Andrew J. Armstrong, honoraria: Astellas Scientific and Medical Affairs Inc. consulting or advisory role: Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Clovis Oncology; Dendreon; Merck; Pfizer; Speakers' Bureau: Bayer; research Funding: Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Patents, Royalties, Other Intellectual Property: Circulating tumour cell novel capture technology (Inst); travel, accommodations, expenses: Astellas Scientific and Medical Affairs Inc. Joseph D. Schonhoft employment: Epic Sciences; stock and other ownership interests - Epic Sciences. Audrey Gill: employment: Epic Sciences; stock and other ownership interests: Epic Sciences; consulting or advisory role - Epic Sciences; Epic Sciences (I); travel, accommodations, expenses - Epic Sciences. Jimmy Zhao has no conflicts of interest to disclose. Ethan Barnett stock and other ownership interests - Biondvax; Gilead Sciences. Emily Carbone has no conflicts of interest to disclose. James Lu employment - Epic Sciences; stock and other ownership interests - Epic Sciences. Emmanuel S. Antonarakis honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi; consulting or advisory role - AstraZeneca; Bayer; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Lilly; Merck; Sanofi; research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst); patents, royalties, other intellectual property - Co-inventor of a biomarker technology that has been licenced to Qiagen; travel, accommodations, expenses - Dendreon; Medivation; Sanofi. Jun Luo consulting or advisory role - Janssen Oncology; Sun Pharma; Tolero Pharmaceuticals; research Funding- Astellas Pharma (Inst); Calibr (Inst); cardiff Oncology (Inst); Constellation Pharmaceuticals (Inst); Gilead Sciences (Inst); Mirati Therapeutics (Inst); Orion Pharma GmbH (Inst); Sanofi (Inst); patents, royalties, other intellectual property - Jun Luo is a co-inventor of a technology assigned to Johns Hopkins University who licenced to Tokai Pharmaceuticals (Inst); Jun Luo is a co-inventor of a technology licenced to A&G Pharmaceuticals (Inst); Jun Luo is a co-inventor of a technology licenced to Qiagen (Inst); Scott T. Tagawa consulting or advisory role: Abbvie; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clovis Oncology; Dendreon; Endocyte; Genentech; Genomic Health; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Tolmar; research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); travel, accommodations, expenses - Amgen; Immunomedics; Sanofi. (OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics; Telix Pharmaceuticals. Qian Yang has no conflicts of interest to disclose. Daniel J. George leadership - Capio BioSciences; honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday; consulting or advisory role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Pfizer; Sanofi; Vizuri; speakers' bureau - Bayer; Exelixis; Sanofi; research Funding- Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst); travel, accommodations, expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi; UroToday. Russell Zelig Szmulewitz honoraria - Astellas Pharma; consulting or advisory role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi; research Funding - Abbvie; Astellas Pharma; Incyte; Janssen Oncology; Macrogenics; patents, royalties, other intellectual property - Patent licenced by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer; travel, accommodations, expenses - Corcept Therapeutics. Daniel Costin Danila honoraria - Angle; Astellas Pharma; AxImmune; Bayer; Clovis Oncology; Janssen Oncology; Pfizer; Pfizer; ScreenCell; consulting or advisory role - Angle; Astellas Pharma; AxImmune; Bayer; Clovis Oncology; Janssen Scientific Affairs; Pfizer; Pfizer; Sanador; research Funding - Genentech; Janssen Research & Development (Inst); Prostate Cancer Foundation; patents, royalties, other intellectual property - GENE EXPRESSION PROFILE ASSOCIATED WITH PROSTATE CANCER; travel, accommodations, expenses - American Austrian Open Medical Institute; Astellas Pharma; Cambridge Healthtech Institute; Genzyme; Janssen Biotech; Janssen Scientific Affairs; Pfizer; Prostate Cancer Foundation; ScreenCell; Stop Cancer. Rick Wenstrup employment - Epic Sciences; leadership - Epic Sciences; stock and other ownership interests - Epic Sciences; Epic Sciences; consulting or advisory role - Blueprint Genetics; Resolys Bio; patents, royalties, other Intellectual Property - patent royalties, AssurexHealth; travel, accommodations, expenses - Epic Systems. Mithat Gonen has np conflicts of interest to disclose. Susan Halabi employment - ASCO; consulting or advisory role - Eisai; Ferring.